Millipore Sigma Vibrant Logo

OP15 Anti-c-ErbB2/c-Neu (Ab-3) Mouse mAb (3B5)

Anti-c-ErbB2/c-Neu (Ab-3), mouse monoclonal, clone 3B5, recognizes the ~185 kDa c-ErbB2/c-Neu protein in HEK293 cells. It is validated for WB, IF, IP, and IHC on frozen and paraffin sections.

Anti-c-ErbB2/c-Neu (Ab-3) Mouse mAb (3B5) MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Anti-HER2, Anti-c-Neu, Anti-ErbB2, Anti-Erythroblastosis Virus

View Products on Sigmaaldrich.com
OP15
View Pricing & Availability

Overview

Replacement Information

Key Spec Table

Species ReactivityHostAntibody Type
H, MMMonoclonal Antibody

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
OP15-100UG
Retrieving availability...
—
Fulfillment and delivery delayed Fulfillment and delivery delayed
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      		 Plastic ampoule 100 μg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      —
      Request Pricing
      		 —
      Description
      OverviewRecognizes the ~185 kDa c-ErbB2/c-Neu protein in HEK293 cells.
      Catalogue NumberOP15
      Brand Family Calbiochem®
      SynonymsAnti-HER2, Anti-c-Neu, Anti-ErbB2, Anti-Erythroblastosis Virus
      Application Data
      Detection of human c-ErbB2/c-Neu by immunoblotting. Sample: Whole cell lysate from HEK293 cells. Primary antibody: Anti-c-ErbB2/c-Neu (Ab-3) Mouse mAb (3B5) (Cat. No. OP15) (1 µg/ml). Detection: chemiluminescence.
      References
      ReferencesMamcs, J.R., et al. 1994. Ann. Surg. 219, 332.
      Tetu, B., et al. 1994. Cancer 73, 2359.
      DiFiore, P.P., et al. 1987. Science 237, 178.
      Slamon, D.J., et al. 1987. Science 235, 177.
      Varley, J.M., et al. 1987. Oncogene 1, 423.
      Bargmann, C.I., et al. 1986. Nature 319, 226.
      Yamamoto, T., et al. 1986. Nature 319, 230.
      Blick, M., et al. 1984. Blood 64, 1234.
      Schwab, M., et al. 1984. Cold Spring Harbor Laboratory 2, 215.
      Product Information
      FormLiquid
      FormulationIn 0.05 M sodium phosphate buffer, 0.2% gelatin.
      Negative controlHepG2 cells or normal skin
      Positive controlSK-BR-3 cells or breast carcinoma tissue
      Preservative≤0.1% sodium azide
      Quality LevelMQ100
      Applications
      Application ReferencesParaffin Sections Meissner, K., et al. 1990. Am. J. Pathol. 137, 1305. Van De Vijver, J.J., et al. 1988. New Engl. J. Med. 319, 1239. Original Clone Van De Vijver, J.J., et al. 1988. New Engl. J. Med. 319, 1239. Immunohistochemistry, Immunoblotting Zhau, H.E., et al. 1990. Mol. Carcinogen. 3, 254. Immunoprecipitation Van De Vijver, J.J., et al. 1988. New Engl. J. Med. 319, 1239.
      Key Applications Frozen Sections
      Immunoblotting (Western Blotting)
      Immunofluorescence
      Immunoprecipitation
      Paraffin Sections
      Application NotesFrozen Sections (2.5 µg/ml)
      Immunoblotting (2-3 µg/ml, see application references)
      Immunofluorescence (2.5 µg/ml)
      Immunoprecipitation (1 µg/sample, see application references)
      Paraffin Sections (2.5 µg/ml, pressure cooker, heat or trypsin pre-treatment required, see application references)
      Application CommentsFor paraffin sections, we recommend pre-treating with a pressure cooker, but trypsin and heat will also work well. Including 0.05% saponin during staining of paraffin sections may help reduce background. In one study ductal carcinomas in situ displaying large-cell, comedo growth type, were stained while none of 16 ductal carcinomas in situ of small-cell, papillary, or cribriform growth type were stained by this antibody. Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogena synthetic peptide (TAENPEYLGLDVPV) corresponding to amino acids 1242-1255 from the C-terminal domain of human c-ErbB2/c-Neu
      ImmunogenHuman
      Clone3B5
      HostMouse
      IsotypeIgG₁
      Species Reactivity
      • Human
      • Mouse
      Antibody TypeMonoclonal Antibody
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Do not freeze Yes
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      OP15-100UG 04055977224658

      Documentation

      Anti-c-ErbB2/c-Neu (Ab-3) Mouse mAb (3B5) SDS

      Title

      Safety Data Sheet (SDS) 

      Anti-c-ErbB2/c-Neu (Ab-3) Mouse mAb (3B5) Certificates of Analysis

      TitleLot Number
      OP15

      References

      Reference overview
      Mamcs, J.R., et al. 1994. Ann. Surg. 219, 332.
      Tetu, B., et al. 1994. Cancer 73, 2359.
      DiFiore, P.P., et al. 1987. Science 237, 178.
      Slamon, D.J., et al. 1987. Science 235, 177.
      Varley, J.M., et al. 1987. Oncogene 1, 423.
      Bargmann, C.I., et al. 1986. Nature 319, 226.
      Yamamoto, T., et al. 1986. Nature 319, 230.
      Blick, M., et al. 1984. Blood 64, 1234.
      Schwab, M., et al. 1984. Cold Spring Harbor Laboratory 2, 215.

      Citations

      Title
    • Peter Nagy, et al. (2005) Decreased Accessibility and Lack of Activation of ErbB2 in JIMT-1 ,a Herceptin-Resistant ,MUC4-Expressing Breast Cancer Cell Line. Cancer Research 65, 473-482.
    • Rita Nahta, et al. (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Research 65, 11118-11128.
      		•
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision02-October-2007 RFH
      SynonymsAnti-HER2, Anti-c-Neu, Anti-ErbB2, Anti-Erythroblastosis Virus
      ApplicationFrozen Sections (2.5 µg/ml)
      Immunoblotting (2-3 µg/ml, see application references)
      Immunofluorescence (2.5 µg/ml)
      Immunoprecipitation (1 µg/sample, see application references)
      Paraffin Sections (2.5 µg/ml, pressure cooker, heat or trypsin pre-treatment required, see application references)
      Application Data
      Detection of human c-ErbB2/c-Neu by immunoblotting. Sample: Whole cell lysate from HEK293 cells. Primary antibody: Anti-c-ErbB2/c-Neu (Ab-3) Mouse mAb (3B5) (Cat. No. OP15) (1 µg/ml). Detection: chemiluminescence.
      DescriptionPurified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with Sp2/0.Ag14 cells (see application references). Recognizes the ~185 kDa c-Erb2/c-Neu protein.
      BackgroundAmplification of the human proto-oncogene c-neu has been reported to occur in approximately 30% of breast carcinomas and measurement of the amplification has been proposed as a useful predictor of disease prognosis. Gene amplification and the resulting overexpression of proto-oncogene encoded p185c-neu is thought to transform cells by chronically stimulating signal transduction pathways and in model systems overexpression of human c-neu induces cellular transformation. In the rat model system, a point mutation has been located within the transmembrane domain of the c-neu oncogene. neu (from neuroglioblastomas) is also referred to as erbB-2 (from erythroblastosis virus) and HER2 (for Human Epidermal Growth Factor Receptor) and was the second of four members of the EGF receptor family to be described.
      HostMouse
      Immunogen speciesHuman
      Immunogena synthetic peptide (TAENPEYLGLDVPV) corresponding to amino acids 1242-1255 from the C-terminal domain of human c-ErbB2/c-Neu
      Clone3B5
      IsotypeIgG₁
      Specieshuman, mouse
      Positive controlSK-BR-3 cells or breast carcinoma tissue
      Negative controlHepG2 cells or normal skin
      FormLiquid
      FormulationIn 0.05 M sodium phosphate buffer, 0.2% gelatin.
      Concentration Label Please refer to vial label for lot-specific concentration
      Preservative≤0.1% sodium azide
      CommentsFor paraffin sections, we recommend pre-treating with a pressure cooker, but trypsin and heat will also work well. Including 0.05% saponin during staining of paraffin sections may help reduce background. In one study ductal carcinomas in situ displaying large-cell, comedo growth type, were stained while none of 16 ductal carcinomas in situ of small-cell, papillary, or cribriform growth type were stained by this antibody. Antibody should be titrated for optimal results in individual systems.
      Storage +2°C to +8°C
      Do Not Freeze Yes
      Toxicity Standard Handling
      ReferencesMamcs, J.R., et al. 1994. Ann. Surg. 219, 332.
      Tetu, B., et al. 1994. Cancer 73, 2359.
      DiFiore, P.P., et al. 1987. Science 237, 178.
      Slamon, D.J., et al. 1987. Science 235, 177.
      Varley, J.M., et al. 1987. Oncogene 1, 423.
      Bargmann, C.I., et al. 1986. Nature 319, 226.
      Yamamoto, T., et al. 1986. Nature 319, 230.
      Blick, M., et al. 1984. Blood 64, 1234.
      Schwab, M., et al. 1984. Cold Spring Harbor Laboratory 2, 215.
      Citation
    • Peter Nagy, et al. (2005) Decreased Accessibility and Lack of Activation of ErbB2 in JIMT-1 ,a Herceptin-Resistant ,MUC4-Expressing Breast Cancer Cell Line. Cancer Research 65, 473-482.
    • Rita Nahta, et al. (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Research 65, 11118-11128.
      		•
      Application referencesParaffin Sections Meissner, K., et al. 1990. Am. J. Pathol. 137, 1305. Van De Vijver, J.J., et al. 1988. New Engl. J. Med. 319, 1239. Original Clone Van De Vijver, J.J., et al. 1988. New Engl. J. Med. 319, 1239. Immunohistochemistry, Immunoblotting Zhau, H.E., et al. 1990. Mol. Carcinogen. 3, 254. Immunoprecipitation Van De Vijver, J.J., et al. 1988. New Engl. J. Med. 319, 1239.

      Related Products & Applications

      Related Products

      Catalogue Number Description  
      OP15L Anti-c-ErbB2/c-Neu (Ab-3) Mouse mAb (3B5) Show Pricing & Availability

      Categories

      Life Science Research > Antibodies and Assays > Primary Antibodies